NYSEAMERICAN:MTNB

Matinas BioPharma (MTNB) Stock Forecast, Price & News

$0.39

+0.01 (+2.48%)

(As of 04:33 PM ET)

Compare

Today's Range: $0.38
▼
$0.41
50-Day Range: N/A
52-Week Range: $0.38
▼
$0.94

Volume: 245,216 shs
Average Volume: 388,879 shs
Market Capitalization: $85.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Profile Analyst Ratings Chart Competitors Earnings Insider Trades Headlines Short Interest Social Media

Matinas BioPharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 664.1% Upside
$3.00 Price Target
Short Interest: Healthy
0.64% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.11) to ($0.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Matinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Matinas BioPharma has a forecasted upside of 664.1% from its current price of $0.39.
Amount of Analyst Coverage
Matinas BioPharma has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.64% of the outstanding shares of Matinas BioPharma have been sold short.
Short Interest Ratio / Days to Cover
Matinas BioPharma has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Matinas BioPharma has recently decreased by 14.11%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Matinas BioPharma does not currently pay a dividend.
Dividend Growth
Matinas BioPharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MTNB.

2.2

News and Social Media Coverage

News Sentiment
Matinas BioPharma has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Matinas BioPharma this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for MTNB on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Matinas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Matinas BioPharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.20% of the stock of Matinas BioPharma is held by insiders.
Percentage Held by Institutions
Only 12.84% of the stock of Matinas BioPharma is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Matinas BioPharma are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Matinas BioPharma is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Matinas BioPharma is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Matinas BioPharma has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Matinas BioPharma (NYSEAMERICAN:MTNB) Stock

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

May 30, 2023 | americanbankingnews.com

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

May 12, 2023 | seekingalpha.com

Matinas Biopharma GAAP EPS of -$0.03 in-line, revenue of $1.1M beats by $0.8M

June 1, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 12, 2023 | markets.businessinsider.com

Maxim Group Remains a Buy on Matinas BioPharma (MTNB)

May 12, 2023 | msn.com

Recap: Matinas BioPharma Hldgs Q1 Earnings

May 11, 2023 | msn.com

Why Matinas BioPharma Stock Is Sinking Today

May 11, 2023 | finanznachrichten.de

Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023 | finance.yahoo.com

Q1 2023 Matinas BioPharma Holdings Inc Earnings Call

June 1, 2023 | Edge On The Street (Ad)

ChatGPT Is Already "Old School"

As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.

May 11, 2023 | finance.yahoo.com

Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

May 10, 2023 | finance.yahoo.com

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates

May 10, 2023 | finance.yahoo.com

Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update

May 3, 2023 | finance.yahoo.com

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023

April 28, 2023 | proactiveinvestors.com

Matinas BioPharma shares lipid nanocrystal platform delivery for emerging anti-fungal drug

April 23, 2023 | benzinga.com

CTI BioPharma Stock (NASDAQ:CTIC), Analyst Ratings, Price Targets, Predictions

April 19, 2023 | msn.com

Matinas jumps 25% to hit four-month high on data for anti-fungal agent

April 18, 2023 | finance.yahoo.com

Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID

March 19, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and MoonLake Immunotherapeutics (MLTX)

March 19, 2023 | finanznachrichten.de

Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

March 18, 2023 | seekingalpha.com

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2022 Earnings Call Transcript

March 18, 2023 | insidermonkey.com

Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2022 Earnings Call Transcript

March 17, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and Spruce Biosciences (SPRB)

March 16, 2023 | finance.yahoo.com

Q4 2022 Matinas BioPharma Holdings Inc Earnings Call

March 15, 2023 | finance.yahoo.com

Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

March 14, 2023 | msn.com

Earnings Outlook For Matinas BioPharma Hldgs

March 8, 2023 | finance.yahoo.com

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

March 2, 2023 | finance.yahoo.com

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

See More Headlines

MTNB Price History

30 days | 90 days | 365 days | Advanced Chart

MTNB Company Calendar

Last Earnings: 3/15/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:MTNB
CUSIP: N/A
CIK: N/A
Web: www.matinasbiopharma.com
Phone: (908) 484-8805
Fax: N/A
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +683.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,000,000.00
Net Margins: -479.18%
Pretax Margin: -479.16%
Return on Equity: -54.49%
Return on Assets: -44.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.88
Quick Ratio: 14.88

Sales & Book Value

Annual Sales: $3.19 million
Price / Sales: 26.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.15 per share
Price / Book: 2.55

Miscellaneous

Outstanding Shares: 217,260,000
Free Float: 197,277,000
Market Cap: $83.23 million
Optionable: Not Optionable
Beta: 2.03

Key Executives

Jerome D. Jabbour
President, Chief Executive Officer & Director

Keith A. Kucinski
Chief Financial Officer

Raphael J. Mannino
Chief Scientific Officer & Senior Vice President

James J. Ferguson
Chief Medical Officer

Hui Liu
Chief Technology Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MTNB Stock - Frequently Asked Questions

Should I buy or sell Matinas BioPharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MTNB shares.
View MTNB analyst ratings or view top-rated stocks.
What is Matinas BioPharma's stock price forecast for 2023?: 2 analysts have issued 12-month target prices for Matinas BioPharma's shares. Their MTNB share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 683.1% from the stock's current price.
View analysts price targets for MTNB or view top-rated stocks among Wall Street analysts.
How have MTNB shares performed in 2023?: Matinas BioPharma's stock was trading at $0.5563 at the beginning of 2023. Since then, MTNB stock has decreased by 31.1% and is now trading at $0.3831.
View the best growth stocks for 2023 here.
Are investors shorting Matinas BioPharma?: Matinas BioPharma saw a decline in short interest in May. As of May 15th, there was short interest totaling 1,400,000 shares, a decline of 14.1% from the April 30th total of 1,630,000 shares. Based on an average daily trading volume, of 444,200 shares, the short-interest ratio is presently 3.2 days.
View Matinas BioPharma's Short Interest.
When is Matinas BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our MTNB earnings forecast.
How were Matinas BioPharma's earnings last quarter?: Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). The company earned $1.06 million during the quarter, compared to analyst estimates of $1.10 million. Matinas BioPharma had a negative trailing twelve-month return on equity of 54.49% and a negative net margin of 479.18%.

What other stocks do shareholders of Matinas BioPharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).
What is Matinas BioPharma's stock symbol?: Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."
Who are Matinas BioPharma's major shareholders?: Matinas BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (1.96%), BlackRock Inc. (1.14%), Private Advisor Group LLC (0.09%), Renaissance Technologies LLC (0.08%), Global Retirement Partners LLC (0.05%) and Modera Wealth Management LLC (0.04%).
View institutional ownership trends.
How do I buy shares of Matinas BioPharma?: Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Matinas BioPharma's stock price today?: One share of MTNB stock can currently be purchased for approximately $0.38.
How much money does Matinas BioPharma make?: Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $83.23 million and generates $3.19 million in revenue each year. The company earns $-21,000,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.
How can I contact Matinas BioPharma?: Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for the company is www.matinasbiopharma.com. The company can be reached via phone at (908) 484-8805 or via email at mtnb@jtcir.com.

This page (NYSEAMERICAN:MTNB) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial